XMD8-92 - ERK 抑制劑 - 生命科學(xué)試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEXMD8-92Cat. No.: HY-14443CAS No.: 1234480-50-2分式: CHNO分量: 474.55作靶點(diǎn): ERK作通路: MAPK/ERK Pathway; Stem Cell/Wnt儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 50 mg/mL (105.36 mM; Need ultraso

2、nic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.1073 mL 10.5363 mL 21.0726 mL5 mM 0.4215 mL 2.1073 mL 4.2145 mL10 mM 0.2107 mL 1.0536 mL 2.1073 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內(nèi)實(shí)驗(yàn) 請根據(jù)您的實(shí)驗(yàn)動物和給藥式選擇適當(dāng)?shù)娜芙獍福渲魄罢埾扰渲瞥吻宓膬湟?，再依次添加助溶?為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；

3、以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.27 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (5.27 mM); Clear solutionBIOLOGICAL ACTIVITY1/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE物活性 XM

4、D8-92種選擇性的 ERK5/BMK1 抑制劑，Kd 為 80 nM。IC50 & Target BMK180 nM (Kd)體外研究 XMD8-92 exhibits the greatest affinity towards BMK1 with a measured dissociation constant (Kd) of 80 nM,while DCAMKL2, TNK1 and PLK4 exhibit Kds of 190, 890 and 600 nM, respectively. XMD8-92 is profiledagainst all detectable kinase

5、s in HeLa cell lysates using the KiNativ method and is found to be about 10-foldmore selective for BMK1 with a IC50 of 1.5 M than the most potent off-targets, TNK1 (IC50=10 M) andACK1 (aka TNK2, IC50=18 M). Other weak off-targets include the kinase domain 2 of RSK1 and RSK2,PIK4A and PIK4B, and FAK.

6、 Notably, MEK5 is not significantly inhibited by XMD8-92 at up to 50 M 1.XMD8-92 shows high selectivity to BMK1 in an in vitro ATP-site competition binding assay against 402kinases as well as in the KiNativ method against all detectable kinases in HeLa cell lysates. XMD8-92 blocksEGF-induced activat

7、ion of BMK1 with IC50 of 240 nM and, with concentration as high as 5 M, XMD8-92 hasno inhibitory effect on ERK1/2 activation by EGF 2.體內(nèi)研究 XMD8-92 significantly inhibits tumor growth in vivo by 95%. The pharmacokinetics of XMD8-92 is evaluatedin Sprague-Dawley rats given a single intravenous or oral

8、 dose. XMD8-92 is found to have a 2.0 hr half lifeclearance of 26 mL/min/kg. XMD8-92 has moderate tissue distribution with a calculated volume of distributionof 3.4 L/kg. XMD8-92 has high oral bioavailability with 69% of the dose absorbed. After a single oral dose of2 mg/kg, maximal plasma concentra

9、tions of approximately 500 nM are observed by 30 minutes, with 34 nMremaining 8 hr post dose. In tolerability experiments, high plasma concentrations of drug (approximately 10 M following IP dosing of 50 mg/kg) are maintained throughout the 14 days. XMD8-92 appeares to be welltolerated and the mice

10、appeared healthy with no sign of distress. No vasculature instability is observed in theXMD8-92-treated mice 1. XMD8-92 treatment in both immunocompetent and immunodeficient mice blockedthe growth of lung and cervical xenograft tumors, respectively, by 95%. This remarkable anti-tumor effect ofXMD8-9

11、2 in lung and cervical xenograft tumor models is due to XMD8-92s capacity to inhibit tumor cellproliferation through the PML suppression-inducted p21 checkpoint protein, and by blocking of BMK1scontribution in tumor-associated angiogenesis. Besides, BMK1 knockout (KO) in mice leads to complete andir

12、reversible removal of the BMK1 protein, while XMD8-92 treatment in mice only suppresses the activity ofBMK1, which is reversible. Second, the vasculature instability observed in BMK1 KO mice may be due tolack of the C-terminal non-kinase domain of BMK1, which is still present during XMD8-92 treatmen

13、t ofanimals 2.PROTOCOLKinase Assay 1 KiNativ profiling of XMD8-92 is carried out with both an ATP and ADP acylphosphate-desthiobiotin with thefollowing modifications. HeLa cell lysates (5 mg/mL total protein) are incubated in the presence of XMD8-92at 50 M, 10 M, 2 M, 0.8 M, and 0 M for 15 minutes p

14、rior to addition of the ATP or ADP acylphosphateprobe (5 M final probe concentration). All reactions are performed in duplicate. Probe reactions proceededfor 10 minutes and the reaction stopped by the addition of urea and processed for MS analysis. Samples areanalyzed by LC-MS/MS on a linear ion tra

15、p mass spectrometer using a time segmented “target list” designedto collect MS/MS spectra from all kinase peptide-probe conjugates that can be detected in HeLa cell lysates.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemEThis target list is generated and validated by prior exhaustive analysis of He

16、La lysates. Up to fourcharacteristic fragment ions for each kinase peptide-probe conjugate are used to extract signals for eachkinase, and a comparison of inhibitor treated to control (untreated) lysates allow for precise determination of% inhibition at each point. A manuscript describing the detail

17、s of this targeted mass spectrometry approach isin preparation 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 1Administration 1 5105 HeLa cells are resuspended in DMEM and injected subcutaneously into the right flank of 6-week-oldNod/Scid

18、 mice (day 0). On the second day (day 1) after tumor cell injection, mice are randomized into 2groups (6 animals, XMD8-92, 1-28 day, and 18 animals, control). The XMD8-92 (1-28 day) group is treatedwith XMD8-92 at the dose of 50 mg/kg twice a day intraperitoneally. The control group receive daily in

19、jectionsof the carrier solution as control. On the day 7, the control group is randomized into 2 groups (6 animals,XMD8-92, 7-28 day, and 12 animals, control). And on the day 14, the remaining control group is randomizedinto 2 groups (6 animals, XMD8-92, 14-28 day, and 6 animals, control). Treatment

20、 with XMD8-92 in XMD8-92 (7-28 day) and XMD8-92 (14-28 day) groups is initiated on day 7 and day 14, respectively. Tumor size ismeasured using a caliper, and tumor volume is determined 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Cancer Cell. 2018 Nov 12;34(5):807-822. Sci Signal. 2014 Oct 28;7(349):ra102. Stem Cell Reports. 2018 Oct 9;11(4):929-943. PLoS One. 2015 Apr 17;10(4):e0125054. Harvard Medical School LINCS LIBRARYSee more customer validat